← All Forte Biosciences, INC filings

Forte Biosciences, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
FBRX
Forte Biosciences, INC
10-K: Forte Biosciences Reports Positive Celiac Data, Secures $75M
Forte Biosciences announced positive Phase 1b celiac disease trial data and successfully raised $75 million in a public offering, while continuing to incur significant net losses.
NASDAQ
FBRX
Forte Biosciences, INC
10-K: Forte Biosciences Reports Full Year 2024 Results, Focuses on FB102 Clinical Development
Forte Biosciences details its financial results for 2024 and provides an update on the clinical development of its lead product candidate, FB102.
NASDAQ
FBRX
Forte Biosciences, INC
10-K/A: Forte Biosciences Files Amended 10-K to Include Omitted Information
Forte Biosciences has filed an amendment to its annual report to include previously omitted information regarding directors, executive compensation, and corporate governance.
NASDAQ
FBRX
Forte Biosciences, INC
10-K: Forte Biosciences Files 10-K, Provides Update on FB-102 Clinical Trial
Forte Biosciences' 10-K filing details the company's financial status, ongoing FB-102 clinical trial, and regulatory landscape.